Does Tirzepatide Cause Hair Loss? Trial Numbers, Why Rapid Weight Loss Sheds Hair, and How to Limit It

Written by Nataliia Bondarchuk. Updated October 26, 2026.

Tirzepatide does cause hair loss in the sense that matters to a person looking at the shower drain: about 5% of people on Zepbound reported it in the trials, against 1% on placebo. It does not cause hair loss in the sense that matters to a dermatologist: the drug does not attack hair follicles, and the shedding has the signature of telogen effluvium, the temporary mass shedding that follows any rapid weight loss, surgery, childbirth or serious illness. That distinction is the whole story. It tells you when the shedding will start (two to four months after the weight starts coming off fast), when it will stop (a few months later, once the rate of loss slows), whether it grows back (yes, in almost everyone), and what actually reduces it (protein, iron and a slower pace, not a different drug).

Below: the trial numbers by dose, why Mounjaro's label does not mention hair loss while Zepbound's does, what telogen effluvium looks like compared with hereditary thinning, the timeline, the nutrients that matter, the tests to ask for, and when a dermatologist should be involved.

Hair loss was not a pre-specified outcome in the tirzepatide trials; it was recorded when participants mentioned it, which means the numbers are a floor rather than a ceiling. Even so, the gap between drug and placebo is consistent and dose-related, and it appears in the trial where people lost the most weight.

Read the last column alongside the fourth. The more weight a trial population lost, the more hair loss was reported, across two different drugs. Mounjaro and Zepbound are the same molecule; the only reason one label mentions alopecia and the other does not is that people with diabetes in the Mounjaro trials lost less weight. A 2024 analysis of health records from the University of British Columbia found the same pattern with semaglutide: a higher rate of hair-loss diagnoses than with an older weight-loss drug, concentrated in women. The weight-loss curve week by week is in tirzepatide weight loss by week.

Each hair on your head cycles through a growth phase lasting years, a brief transition, and a resting phase of about three months, after which it falls out and a new hair grows. At any moment around 85% to 90% of hairs are growing and 10% to 15% resting. Telogen effluvium is what happens when a shock to the system, a big calorie deficit, surgery, high fever, childbirth, a thyroid swing, pushes a much larger share, sometimes 30% or more, into the resting phase at once. Nothing happens for about three months, because resting hairs do not fall immediately. Then they all let go together, and a person who has been quietly losing weight for a few months suddenly finds handfuls in the brush.

The trigger with tirzepatide is the speed and size of the deficit. The body reads a sudden drop in calories, protein and micronutrients as a famine and reallocates resources away from hair, which is metabolically expensive and biologically optional. The drug has no known direct effect on follicles. This is why the shedding tends to arrive two to four months after the dose reaches a level that produces fast weight loss, why it is worse in people who under-eat protein, and why it is the same with semaglutide, bariatric surgery and crash diets. The second contributor is less discussed: losing fat also lowers estrogen in women and changes the balance of hormones that influence hair, which can unmask hereditary thinning that was already under way.

Most tirzepatide hair loss is the first column. A widening part that began before the drug, or that continues after the shedding phase ends, is the second, which tirzepatide can accelerate but does not create. Anything in the third column is not related to the drug and should be seen promptly.

The schedule shifts with the dose ladder. Someone who stalls at 5 mg and loses slowly may never shed noticeably; someone who climbs to 15 mg in five months and loses 40 pounds may shed heavily in month four. If shedding is still heavy at month seven or starts again after settling, that usually means weight loss is still rapid, protein is still short, or something else is going on.

You cannot prevent telogen effluvium entirely once a large deficit is under way, but you can shrink the trigger and shorten the recovery.

Food choices that cover protein and micronutrients without aggravating nausea are listed in best foods to eat on tirzepatide.

Rarely, and it usually backfires. Stopping the drug does not reverse the shedding that is already scheduled; the hairs that entered the resting phase two months ago will fall out regardless. What stopping does reliably is bring back the weight, with everything that came with it. If hair loss is severe, the better levers are a dose pause or reduction to slow the loss while nutrition catches up, which the label allows, and a dermatologist visit to rule out other causes. Switching to semaglutide does not help, because the cause is the weight loss, not the molecule; the comparison in tirzepatide vs semaglutide covers the side-effect profiles side by side. What happens after stopping is in what happens when you stop tirzepatide.

Hair is one of several tissues that respond to a fast deficit. Skin loses volume faster than it can retract, which is the origin of the loose skin and facial changes described in tirzepatide face and loose skin. Muscle is lost alongside fat unless protein and resistance exercise are maintained; see tirzepatide and muscle loss. Nails can become brittle for the same reason as hair, on the same delay. All of these improve as the rate of loss slows, and all respond to the same three things: pace, protein, and micronutrients. The full list of trial side effects is on our tirzepatide side effects page.

Shedding often arrives alongside fatigue in the same months of treatment, and the two share several causes, including low iron and protein; see does tirzepatide make you tired.

Tirzepatide is associated with hair loss in about 5% of people in the obesity trials, five times the placebo rate, and the reason is the thing the drug does best: fast, substantial weight loss. The shedding is telogen effluvium, arrives two to four months after rapid loss begins, lasts a few months and grows back in almost everyone. The drug does not damage follicles, and switching to a different GLP-1 drug changes nothing. What changes the outcome is pacing the loss to around 1% of body weight a week, eating enough protein, and checking the iron, thyroid and vitamin levels that rapid weight loss most often depletes. If the pattern does not match, patchy, painful, or persisting past six months, that is a dermatologist's question rather than a tirzepatide one.

General information based on published trials and labels. Hair loss with an unusual pattern should be assessed by a dermatologist.